0.6962

0.34% -0.0024

Atossa Therapeutics Inc (ATOS)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Atossa Therapeutics Inc stock is traded at $0.6962, with a volume of 434.45K. It is down -0.34% in the last 24 hours and down -6.55% over the past month. Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Previous Close:

$0.6986

Open:

$0.6969

24h Volume:

434.45K

Relative Volume:

0.66

Market Cap:

$89.93M

Revenue:

Net Income/Loss:

$-26.91M

P/E Ratio:

-3.1645

EPS:

-0.22

Net Cash Flow:

$-19.57M

1W Performance:

-7.64%

1M Performance:

-6.55%

6M Performance:

-53.89%

1Y Performance:

-61.32%

1-Day Range:

$0.68

$0.7023

1-Week Range:

$0.68

$0.77

52-Week Range:

$0.66

$2.31

Atossa Therapeutics Inc Stock (ATOS) Company Profile

Name

Atossa Therapeutics Inc

Sector

Healthcare (1166)

Industry

Biotechnology (671)

Phone

206.588.0256

Address

10202 5TH AVENUE NE, SEATTLE, WA

Employee

Twitter

@atossainc

Next Earnings Date

2025-03-25

Latest SEC Filings

ATOS's Discussions on Twitter

Compare ATOS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ATOS Atossa Therapeutics Inc	0.6962	89.93M	0	-26.91M	-19.57M	-0.22
VRTX Vertex Pharmaceuticals Inc	492.69	131.41B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	637.36	72.26B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	589.15	35.93B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	268.46	34.75B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	267.39	28.24B	3.81B	-644.79M	-669.77M	-6.24

Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-26-18	Initiated	Maxim Group	Buy

Atossa Therapeutics Inc Stock (ATOS) Latest News

Mar 29, 2025

Atossa Therapeutics, Inc. (NASDAQ:ATOS) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 29, 2025

Atossa therapeutics director Remmel H. Lawrence buys $7,000 in stock By Investing.com - Investing.com Canada

Mar 29, 2025

Q1 EPS Forecast for Atossa Therapeutics Boosted by Analyst - Defense World

Mar 29, 2025

Mar 28, 2025

Atossa Therapeutics’ Earnings Call Highlights Cost Reductions and Clinical Progress - TipRanks

Mar 28, 2025

Atossa therapeutics director Remmel H. Lawrence buys $7,000 in stock - Investing.com India

Mar 28, 2025

All You Need to Know About Atossa Genetics (ATOS) Rating Upgrade to Buy - Yahoo Finance

Mar 28, 2025

Atossa Therapeutics (NASDAQ:ATOS) Earns Buy Rating from HC Wainwright - Defense World

Mar 28, 2025

Mar 26, 2025

We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth - Yahoo Finance

Mar 26, 2025